LEADER 01041nam0 22002651i 450 001 SUN0036184 005 20050513120000.0 010 $a18-421-7137-2 100 $a20050513d2004 |0engc50 ba 101 $aeng 102 $aGB 105 $a|||| ||||| 200 1 $aGreek Art in View$eessays in honour of Brian Sparkes$fedited by Simon Keay and Stephanie Moser 210 $aOxford$cOxbow Books$d2004 215 $a172 p.$cill.$d25 cm. 620 $aGB$dOxford$3SUNL000020 700 1$aKeay$b, Simon$3SUNV030387$0156738 701 1$aMoser$b, Stephanie$3SUNV030388$0728088 712 $aOxbow$3SUNV003067$4650 801 $aIT$bSOL$c20181109$gRICA 912 $aSUN0036184 950 $aUFFICIO DI BIBLIOTECA DEL DIPARTIMENTO DI LETTERE E BENI CULTURALI$d07 CONS E 2134 $e07 16197 995 $aUFFICIO DI BIBLIOTECA DEL DIPARTIMENTO DI LETTERE E BENI CULTURALI$bIT-CE0103$h16197$kCONS E 2134$oc$qa 996 $aGreek Art in View$91422959 997 $aUNICAMPANIA LEADER 00872nam--2200313---450 001 990002033270203316 005 20200504075739.0 035 $a000203327 035 $aUSA01000203327 035 $a(ALEPH)000203327USA01 035 $a000203327 100 $a20040928d1993----km-y0itay0103----ba 101 0 $aita 102 $aIT 105 $aa---||||001yy 200 1 $aKing John$edal testo alla scena$fscritti di P. Pugliatti ... [et alt.]$ga cura di Mariangela Tempera 210 $aBologna$cCLUEB$d1993 215 $a219 p., [20] carte di tav.$cill.$d22 cm 606 0 $aTeatro 676 $a792 702 1$aPUGLIATTI,$bP. 702 1$aTEMPERA,$bMariangela 801 0$aIT$bsalbc$gISBD 912 $a990002033270203316 951 $aXVII A. 1837$b1507 DLAS$cXVII A.$d00349581 959 $aBK 969 $aCAS 996 $aKing John$91386809 997 $aUNISA LEADER 01698nam 2200349 450 001 9910688456203321 005 20230630044620.0 035 $a(CKB)5400000000044771 035 $a(NjHacI)995400000000044771 035 $a(EXLCZ)995400000000044771 100 $a20230630d2021 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAdvances in Precision Medicine Oncology /$fHilal Arnouk, Bassam Hassan, editor 210 1$aLondon :$cIntechOpen,$d2021. 215 $a1 online resource (260 pages) 311 $a1-83968-869-6 330 $aRecent advances in precision medicine and immuno-oncology have led to highly specific and efficacious cancer therapies such as monoclonal antibodies and immune checkpoint inhibitors (ICIs). This book provides an up-to-date overview of advances in the field of immuno-oncology. Chapters cover such topics as ICIs and how they mount a robust immune response against cancer cells as well as the response of ICIs to treatment predictive biomarkers and their potential immune-related adverse events (irAEs). Additionally, the book includes a comprehensive review of the powerful FDA-approved therapeutic agent doxorubicin, highlighting the molecular mechanisms behind doxorubicin's drug resistance and critical side effects. 606 $aCancer$xTreatment 615 0$aCancer$xTreatment. 676 $a616.99406 702 $aHassan$b Bassam 702 $aArnouk$b Hilal 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910688456203321 996 $aAdvances in Precision Medicine Oncology$92828415 997 $aUNINA